ERBB2 and neoplasm: Strikingly, treatment with an ERBB2 inhibitor drastically reduced the formation of liver metastasis (Fig. 6b), whereas ERBB2 knock-out in vitro did not affect SCLC tumor cell proliferation (Supplementary Fig. 4c, d).